About the
The ALPHA3 study will evaluate an investigational CAR T-cell therapy called cemacabtagene ansegedleucel (or “cema-cel,” pronounced “SEM-a-sell”) in patients with B-cell lymphoma after they have completed their initial (first line) treatment, typically chemotherapy. “Investigational” means that it has not been approved by the FDA at this time. The ALPHA3 trial incorporates an investigational diagnostic blood test to determine if patients with DLBCL or a similar type of lymphoma are found to have what is known as minimal residual disease (MRD). Research shows that patients who are MRD negative (MRD-) are unlikely to have their cancer return. However, patients who test MRD+ are considered to be at high risk of their cancer coming back, also known as relapse, and may be eligible to proceed to the next step and continue participating in this clinical study.
What Are the Potential Benefits?
The information that doctors and researchers learn from the ALPHA3 study may help improve what they know about treatments for adult patients with diffuse large B-cell lymphoma (DLBCL) and similar types of lymphoma, and may potentially help other people in the future. Additionally, knowing your MRD status – whether positive or negative – may provide additional information about your prognosis and could help you plan for your future. If you are MRD-, this may provide peace of mind that your cancer is statistically unlikely to return. On the other hand, knowing if you are MRD+ may allow you to take steps to try and lessen its chances of coming back, such as deciding to participate in the second step of the ALPHA3 study. An empowered, proactive approach to your cancer is here, and you may be eligible to take part.
What Is Being Tested?
The main goals of this clinical trial are to predict who is at high risk of their cancer returning, and to explore whether treatment with an investigational CAR T-cell therapy (cema-cel) can stop it before it returns. Read our FAQs to learn more about this screening and study, and what to expect as a participant.
From the Community…
There are clinical trials out there. I don’t want to just sit here and let it overtake me, I want to feel like I’m battling back, even just a little bit.
If I have the opportunity to help myself and help other people who are dealing with my condition, if that's the way I can contribute, sign me up.
Without the first person with the first step, you never know what greater good could come.
If you’re not doing clinical trials, you’re not making progress. The more people examining it and studying it, the better.Patients featured are connected to other clinical trials, apart from ALPHA3.
Clinical Trials Make A Difference
When you participate in a clinical study, you provide valuable information that could eventually lead to a better treatment and – if successful – to better outcomes. Take our brief survey to see if you are a good fit. Completing the survey comes with no obligation.
Participate In Innovation
Shape The Future
Help Others
Still Have Questions?
Still have questions? Contact us anytime via email.